



Poster Session 3
12:30 – 2:00 p.m.
Thursday, December 12

P3-01-01: Innovative Approaches to Breast Cancer Awareness: The Impact of Virtual Navigation and Future Digital Solutions	Manisha Salinas
P3-01-02: Impact of race, socioeconomic status and clinicopathological features on clinical outcomes in triple negative breast cancer in the ECOG-ACRIN EA1131 trial	Sonya Reid
P3-01-03: The impact of race on outcomes of immune checkpoint inhibitor in triple-negative breast cancer patients: NCDB data analysis	Andrew Liu
P3-01-04: Racial and ethnic disparities in the development of second primary solid tumor malignancies in breast cancer survivors	Kriti Ahuja
P3-01-05: The Effect of Individual and Neighborhood-level Socioeconomic Disparities in Advanced and Early-Onset Female Breast Cancer	Anumita Chakraborty
P3-01-06: Differences in health-related quality of life among breast cancer survivors by Hispanic origins	Eunkyung Lee
P3-01-07: Breast Cancer Survival According to Health Insurance Coverage in Brazil: Results from the Prospective AMAZONA III Study (GBECAM 0115)	Daniela Dornelles Rosa
P3-01-08: The prevalence of biomarker alterations, treatment patterns, and survival in metastatic triple-negative breast cancer by race: A national cohort study	Pegah Farrokhi
P3-01-09: Feasibility of providing rural patients with telehealth consultation coupled with in-person intervention at tertiary oncology center	Natasha Hunter
P3-01-10: Racial and ethnic disparities in the development of hematological second primary malignancies in breast cancer survivors	Kriti Ahuja

P3-01-11: Racial Disparity in the Screening and Diagnosis of Breast Cancer in the Public Health System (SUS) in Brazil	Juliana Francisco
P3-01-12: Enhancing Adherence to Hormone Therapy among Latina Breast Cancer Patients Impacted by Social Determinants of Health through a Bilingual, Culturally Tailored Mobile App and Patient Navigation	Patricia Chalela
P3-01-13: Race and response to neoadjuvant chemotherapy for nonmetastatic breast cancer using the SEER database.	Alvaro Alvarez Soto
P3-01-14: DARC/ACKR1, Duffy-Null and African ancestry influence on immune response in triple negative breast cancer	Yanira Guerra
P3-01-15: Exploring the Impact of Race, Ethnicity, and BMI on Neoadjuvant Hormonal Treatment Outcomes	Traci King
P3-01-16: Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degradator, Plus Palbociclib in CDK4/6 Inhibitor-Resistant WT ER and ER Y537S Mutant Patient-Derived Xenograft (PDX) Models	Jessica Teh
P3-01-17: Transcriptomic and phenotypic profiling of circulating tumor cells from metastatic breast cancer patients	Michela Palleschi
P3-01-18: Clinical validation of image-based AI predictive biomarkers for precision neoadjuvant triple-negative breast cancer treatment (PEAR-TNBC): Interim results from Cohort A	Peter Hall
P3-01-19: Proteomics-based degradome analysis of mammary tumor adjacent adipocyte reveals adipocyte-derived peptide MASP6 promotes breast cancer cell invasion and migration	Shuhan Zhao
P3-01-20: A novel, semi-automated Pipeline for HER2 Quantification on CTCs in breast cancer patients. Is cytopathology of peripheral blood a new diagnostic option?	Nadia Bayou
P3-01-21: Gene expression changes following pre-operative letrozole therapy among postmenopausal women with estrogen-receptor positive HER2/neu-negative invasive breast cancer	Simone Dekker
P3-01-22: Pilot Feasibility Study of ctDNA Testing in Breast Cancer and its Association with Pain, Stress and Anxiety	Mrinalini Ramesh
P3-01-23: MELK controls stromal components through fibronectin modulation in highly aggressive breast cancers.	Mohd Mughees
P3-01-24: Triple negative and non-triple negative breast cancer have distinct metabolic characteristics associated with divergent survival outcomes	Heidi Ko
P3-01-25: Molecular and immunological characterization of HER2-low, HER2 ultra-low, and HER2-null male breast cancer	Dario Trapani

P3-01-26: Amitriptyline potentiates Elacestrant in treating ER positive ESR1 mutant Breast cancer.	Prabhakar Pitta Venkata
P3-01-27: CYTOKINE LEVEL AND OUTCOMES OF NEOADJUVANT TREATMENT IN EARLY BREAST CANCER	Salome Khutsurauli
P3-01-28: Therapeutic Yoga Enhances Cognitive and Metabolic Markers in Breast Cancer Survivors	Minal Sonawane
P3-01-29: Open, single-arm clinical trial with innovative inPROBE® technology for in vivo, real-time, quantitative HER2 expression assessment	Dariusz Stencel
P3-01-30: Precision and Repeatability of PD-L1 Detection using PD-L1 IHC 22C3 pharmDx in Breast Cancer	Emily Olander
P3-02-01: Is Autologous Fat Grafting a Safe Option or a Risk of Cancer Recurrence in Women with Breast Cancer Who Carry Germline Pathogenic Variants?	Lucrezia Raimondi
P3-02-02: Genetics and Breast Cancer: Insights and Challenges from Two Years of Analysis of the Private Health System in Brazil.	Letícia Linhares
P3-02-03: HEPARANASE LIQUID BIOPSY AND BREAST CANCER	Daniel Gimenes
P3-02-04: Phase II, Single Arm Trial of Denosumab's Effect on Breast Density and Breast Tissue Biomarkers	Patricia Thompson
P3-02-05: Mitochondrial Metabolism-Related Features Guiding Precision Subtyping and Prognosis in Breast Cancer, Revealing FADS2 as a Novel Therapeutic Target	Yangyang Cui
P3-02-06: Prevalence of BRCA1/2 Mutations in Low ER Positive/HER2 Negative Breast Cancer: Clinico-Pathological Parameters and Comparisons with Unselected TNBC	Ji Won Yoo
P3-02-07: Breast Cancer Polygenic Risk Score and Patient Survival Outcomes Among Caucasians	Arya Mariam Roy
P3-02-08: Incorporating Breast Radiomics and Body Mass Index to Improve Breast Cancer Risk Prediction in Minority Women	Sara Wallam
P3-02-09: Correlation between risk groups and molecular subtype of breast cancer with metabolic syndrome and ethnicity	Sharda P. Singh
P3-02-10: Evaluation of a polygenic risk score as a predictor of breast cancer, triple-negative breast cancer, and early-onset disease in Hispanic women.	Holly Pederson
P3-02-11: CDH1 genotype exploration in phenotype-first approach with hereditary lobular breast cancer syndrome	Giovanni Corso
P3-02-12: Hereditary breast cancer risk assessment and referral at a high-volume, diverse mammography clinic	Emily Podany
P3-02-13: Global disparities in breast cancer screening programs and breast cancer mortality	Syed Mahfuz Al Hasan

P3-02-14: Clinicopathogenomic analysis of Japanese metastatic breast invasive lobular carcinoma	Masaki Makita
P3-02-15: Combined Therapy of Progesterone Receptor Antagonist and COX-2 Inhibitor Prevents BRCA1-Deficient Mammary Tumorigenesis in Mice: A Novel Synthetic Lethal Strategy for Breast Cancer Prevention	Oukseub Lee
P3-02-17: tRF-1432—a novel target for reversing chemoresistance in breast cancer	Yuhan Dai
P3-02-18: Multi omics reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance invasive lobular carcinoma	Annapurna Gupta
P3-02-19: Simultaneous loss of BRCA2 and RB1 results in growth disadvantage but strong CDK4/6i resistance in HR+/HER2- breast cancer	Daniela Haas
P3-02-20: CDK4/6 inhibitor resistance in patients with ER+ breast cancer: Identification and characterization of resistance mechanisms in thirty-two XPDX models	Delaney Rushing
P3-02-21: Generation of Sacituzumab Govitecan Resistant Breast Cancer Models	Carson Walker
P3-02-22: The role of circular RNAs in triple-negative breast cancer and chemotherapy resistance	Xiyin Wang
P3-02-23: Evaluation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal novel therapeutic opportunities in ER+/HER2- breast cancers	Srinivasan Madhusudan
P3-02-24: Quantitative changes in hormone receptor- and Ki67- levels in response to short-term neoadjuvant endocrine therapy in breast cancer	Rehaan Machhi
P3-02-25: CRISPR/Cas9 knockout of ALDH1A1 increases radiation response in triple-negative breast cancer	Grace Aijayi
P3-02-26: Sex-biased cancer cells induce endocrine therapy resistance and immune suppression in male breast cancer	Zhishuang Gao
P3-02-27: circAXIN1 promotes EMT-mediated metastasis and doxorubicin resistance via Wnt/ β -catenin pathway by regulating miR-486-3p/BCL11A axis in TNBC	YAN LIU
P3-02-28: A combination approach to target residual tumors via ferroptosis induction	Yulin Li
P3-02-29: The mechanism of acidic microenvironment promotes tumor-associated macrophages secreting glutamine to activate dual signaling pathways of mTORC1 and c-MYC in CDK4/6 inhibitor resistance of ER-positive breast cancer	Fanli Qu

P3-02-30: PIK3CA hotspot mutations as biomarkers for prognosis and treatment prediction in ER+/HER2- postmenopausal breast cancer patients	Gizeh Perez Tenorio
P3-03-01: Awareness of Rare Cancers: Hearing and Engaging Rural Communities (ARCHER-C)	Beau Blass
P3-03-02: Effects of socioeconomic status on access to next-generation sequencing in patients with metastatic breast cancer	Christine Zhang
P3-03-03: Disparities in Quality of Life Among Breast Cancer Survivors in the All of Us Research Program	Gagandeep Kaur
P3-03-04: "Racial Disparities in Endocrine Response Pathway Activity in ER-Positive Breast Cancer: Insights from a Window of Opportunity Trial"	Robert Babkowski
P3-03-05: Title: Impact of Comorbidities on Mortality, Length of Stay, and Hospital Charges in Breast Cancer Patients: A National Inpatient Sample Analysis	Kalaivani Babu
P3-03-06: Treatment and Survival Outcomes for Transgender and Gender-Diverse Patients with Breast Cancer from 2004–2022 in the National Cancer Database	Kelley Chan
P3-03-07: Efficacy of Immunotherapy in Older Patients with Triple-Negative Breast Cancer: A Systematic Review	Marie Liu
P3-03-08: Clinical Characteristics of Male Breast Cancer by Race and Factors Predicting Survival: An updated analysis	Jayasree Krishnan
P3-03-09: Evaluating the impact of race, ethnicity, and neighborhood-level socioeconomic factors on invasive lobular carcinoma incidence and survival in the United States	Kathryn Demanelis
P3-03-10: Leverage GPT-4 and social media to understand health disparity for transgender patients with breast and gynecological cancers.	Kathryn Mishkin
P3-03-11: Structural Racism and Aggressive Breast Cancer Biology	Neha Goel
P3-03-12: Social Determinants of Health (SDOH) and Z Code Utilization among Patients with Breast Cancer (BC)	Nehanda Jones
P3-03-13: Ethnic and Geographic Disparities in Mucinous Breast Cancer	Inae Park
P3-03-14: Concordance of Self-Reported Demographic and Clinical Variables with Data from the State Cancer Registry among Breast Cancer Survivors of Hispanic Descent	Maria Eduarda de Azevedo Daruge
P3-03-15: Racial differences in incidence of depression, anxiety, and insomnia among breast cancer patients on endocrine therapy	Shuwen Lin

P3-03-16: Molecular stromal signature to predict Ductal Carcinoma in Situ (DCIS) progression	Niki Prekete
P3-03-17: Genetic Profiles and Precision Medicine in Adolescent and Young Adult Chinese Women with Breast Cancer: A Comprehensive Study	Chengyi Wang, Qing Hao
P3-03-18: Hormone receptor status and PD-L1 expression prevalence in breast cancer when assessed with PD-L1 IHC 22C3 pharmDx and Combined Positive Score	Joseph Barreto
P3-03-19: Somatic Mutation Profile of Metastatic Breast cancer in Brazilian Patients using Next Generation Sequencing	Mariana Ferreira
P3-03-20: A multicenter retrospective review of clinical-pathological characteristics associated with survival outcomes in a large cohort of metaplastic breast cancer patients.	Naomi Dempsey
P3-03-21: EFFECT OF REGULATORY T CELL INFILTRATION ON PATHOLOGICAL COMPLETE RESPONSE RATES WITH NEOADJUVANT THERAPY IN LOCAL AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER	Derya Kivrak Salim
P3-03-22: CK2 in breast cancer and associated clinical characteristics	Nicholas Wilson
P3-03-23: Targeting of SEMA7A Signaling Improves Response to Endocrine Therapy in ER+ BC	Rachel Steinmetz
P3-03-24: Assessment of cell signaling pathway activity and expression of MKI67, ESR1 and ERBB2 as profiling tool for selection of targeted therapy in breast cancer	Robert Babkowski
P3-03-25: High expression of microRNA-486 levels can be a prognostic biomarker for better survival in ER-positive breast cancer patients	Yoshihisa Tokumaru
P3-03-26: Long-Read Nanopore Sequencing for the Identification of Gene Fusion-Derived Breast Cancer Neoepitopes	Skylar Henry
P3-03-27: Klotho proteins and small non-coding RNAs as potential prognostic markers and therapeutic targets for human triple-negative breast cancer and canine mammary carcinoma.	Luciana Mayer Kluppel
P3-03-28: Integrative Bioinformatics Approach Reveals Potential Liquid Biopsy-based Biomarkers for Breast Cancer Metastasis Monitoring	Hideki Hideki
P3-03-29: Calcification characteristics in women with benign breast disease and the risk of subsequent breast cancer: a case-control study	Merle van Leeuwen
P3-03-30: Molecular landscape of breast cancer in pre- and postmenopausal women	Sameer Udhane

P3-04-01: Extracting Chromatin Signatures from Breast Cancer Using Open Chromatin Guided Machine Learning	Sakuntha Gunarathna
P3-04-02: Advanced Breast Cancer by Region in the Hawaii and Pacific Islands Mammography Registry	Dustin Valdez
P3-04-03: Per- and Polyfluoroalkyl Substances (PFAS) in Drinking Water and Breast Cancer Risk among Women in the Military	Celia Byrne
P3-04-04: The Butyrate Transporter SLC5A8 Selectively Inhibits Breast Tumor Metastasis	SONIA BATAN
P3-04-05: Expression analysis reveals clues to the molecular mechanisms driving breast cancer risk in women with benign breast disease	Michele Cote
P3-04-06: Genomic and transcriptomic profiling of BRCA mutation carrier tissues reveals the landscape of early pathogenesis of BRCA1/2-associated breast cancer	Zuen Ren
P3-04-07: Modeling BRCA1 and BRCA2 Mammary Tissues and Estrogen Positive Breast Cancer Using iPSC-Derived Organoid Models	Simon Gayther
P3-04-08: Redefining Bravery: A New Paradigm for Helping Young Women Understand Their Risk for Early Onset Breast Cancer	Ally Moehring
P3-04-09: Comprehensive Analysis of Rare Variants Associated with Genetic Predisposition to Non-BRCA Familial Breast Cancer Among Arabs	0 0
P3-04-10: Integrated germline and tumor whole genome sequencing to identify novel hereditary breast cancer genes in women with very early onset breast cancer	Lily Owens
P3-04-11: Perceptions, Attitudes, and Education of Oncology Health Care Providers Regarding Genetic Testing and Counseling in a Resource-Restricted Country.	Lulwa El Saket
P3-04-12: Quantitative evaluation and assessment using the automated volumetric breast density measurement software Volpara Density in Japanese women	Saori Hayashi
P3-04-13: Characterization and Comparison of Breast White Adipose Tissue Inflammation in Nigerian and African American Women with Primary Breast Cancer	Peter Ntiamoah
P3-04-14: Title: Case report of Breast cancer in a transgender PALB2 pathogenic variant carrier taking hormone therapy	Jessica McMillan
P3-04-15: Dietary-Advanced Glycation End products and breast cancer risk: Evaluating MYC dependency within the context of AGE-RAGE signaling in cancer associated fibroblasts	Gowtami Aishwarya Panguluri

P3-04-16: Tumor Tissue Slices from Breast Cancer Patient Derived Xenografts as an Ex Vivo Method for Treatment Response	John Landua
P3-04-17: 16q is a breast cancer suppressor arm	Sean Egan
P3-04-18: An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer	Claudia Galassi
P3-04-19: Metronomic cyclophosphamide/iodine is proposed as an effective treatment for breast cancer: comparing intraperitoneal and oral administration in a murine model.	Evangelina Delgado-González
P3-04-20: Anti-cancer Efficacy of Natural Killer Cells in Breast Cancer Cell Lines and Patient-derived Organoids	ILKYUN LEE
P3-04-21: Optimization of lentiviral transduction of a triple-negative breast cancer patient-derived xenograft organoid for modeling tumor cell quiescence and associated treatment resistance	Darien Reed-Perino
P3-04-22: An organoid model derived from a patient with breast angiosarcoma	Xiaoling Liu
P3-04-23: Utilization of a novel breast microphysiological system to investigate the influence of tumor microenvironment on hormone receptor positive breast cancer	Megan Benz
P3-04-24: Targeting nucleosome synthesis as a therapeutic strategy for triple-negative breast cancer	Joshua Gruber
P3-04-25: Investigating Proteostasis in Endocrine Therapy-Resistant Luminal A Breast Cancer	Anthony Peidl
P3-04-26: DCIS turns fatal: Thrombotic microangiopathy as the cause of death in undiagnosed recurrent metastatic breast cancer	Samantha El Warrak
P3-04-27: Resistance to neratinib in HER2+ breast cancer: Mechanistic insights and treatment approaches	Fu-Tien Liao
P3-04-28: Inhibition of FASN and ACC1 as a Potential Treatment for Advanced Endocrine Therapy-Resistant Breast Cancer	Henriette Balinda
P3-04-30: Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer	Yuki Matsunaga
P3-05-01: Social Determinants of Health in Patients with Metastatic Breast Cancer in Mexico	Haydee Verduzco-Aguirre
P3-05-02: The impact of ethnicity on benefit from novel drugs approved for breast cancer treatment: a systematic review and meta-analysis of randomized phase 3 trials of the last decade.	EMMA ZATTARIN
P3-05-03: Using large-scale, population- or hospital-based data, to identify disparities by race in the use of Oncotype DX: a systematic review	Fabio Girardi

P3-05-04: Understanding access to HER2-targeted therapy among breast cancer patients treated in a resource-constrained setting: Cross-sectional observational cohort analyses	Mounika Reddy Guru
P3-05-05: A Comprehensive Study of Breast Cancer Mortality and DALY Trends considering Smoking as a Risk Factor from 1991-2021 in the USA and exploring the State-level disparities	Vaibhavi Mukhtiar
P3-05-06: The Development of a Hispanic/Latinx Breast Cancer Clinic	Claudia Tellez
P3-05-07: Early Pilot Results From the Navigator-Assisted Hypofractionation (NAVAH) Program to Aid African-American Breast Cancer Patients	Shearwood McClelland III, M.D.
P3-05-08: Examining Racial Disparities in the Association between Food Swamps, Liquor Store Density, and Postmenopausal Breast Cancer Mortality among Georgia Cancer Center Patients	Malcolm Bevel
P3-05-09: Invasive Lobular Carcinoma Has Aggressive Molecular Subtypes in African American Women	Genevra Magliocco
P3-05-10: Racial Disparities in Clinical Trials of PARP Inhibitors for Breast Cancer - A Comprehensive Review	Elizabeth John
P3-05-11: Patient Experience and Perceptions Related to Breast Health, Mammography and Artificial Intelligence in Healthcare	Nancy Brinker
P3-05-12: The Prognostic Impact of Stress, High Levels of Tumor Infiltrating Lymphocytes and Race in Women Diagnosed with Triple Negative Breast Cancer	Himaja Gaddipati
P3-05-13: Determinants for concordance of ASCO quality of care measures in women with breast cancer in a Brazilian cohort	Anne Dominique Nascimento Lima
P3-05-14: Male Breast Cancer Disparities & Demographics: A National Inpatient Sample Database Analysis & Literature Review	Akshit Chitkara
P3-05-15: Race, Stress, and Breast Cancer: A Scoping Review	Noon Eltoun
P3-05-16: Extreme ESR1 polyclonality, mutational dynamics and effects on treatment outcomes in patients with ER+ metastatic breast cancer	Tess O'Meara
P3-05-17: Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer - A multicenter retrospective study	Yuri Takamatsu
P3-05-18: Prognostic value of circulating tumor DNA (ctDNA) dynamics and protein biomarkers in patients treated with alpelisib (ALP) and endocrine therapy (ET) for HR+/HER2- PIK3CA-mutated advanced breast cancer (ABC) in all 3 cohorts of the phase II BYLieve study	Dejan Juric

P3-05-19: High Prevalence of HER2-Low and Increased TIL Levels in ILC Patients with Residual Disease Following Neoadjuvant Therapy Provides a Rational for use of HER2-Antibody-Drug Conjugates or Immunotherapy Approaches	Melinda Sanders
P3-05-20: Novel liquid biopsy technology reveals cancer-specific isoforms for breast cancer diagnosis and therapy	Richard Kuo
P3-05-21: Multicenter retrospective cohort study of the sequential use of antibody drug conjugates trastuzumab deruxtecan & sacituzumab govitecan in patients with HER2 low metastatic breast cancer: a subgroup analysis of next generation sequencing results.	Reshma Mahtani
P3-05-22: Prognostic Significance of Tumor-informed Personalised Circulating Tumor DNA Monitoring in Breast Cancer Patients Undergoing Neoadjuvant Therapy	Yunjiang Liu
P3-05-23: Single nucleus chromatin accessibility and transcriptome analyses reveal aberrant inter-cellular communication in inflammatory breast cancer	Harikrishna Nakshatri
P3-05-24: Mapping the Genomic Landscape: Comprehensive Profiling of Diverse Histological Types of Breast Cancer	Taro Yamanaka
P3-05-25: Dynamic increases in T cell repertoire diversity determine palbociclib efficacy and improved antitumor immune response	Sara Cabrero de las Heras
P3-05-26: Efficacy of first-line CDK4/6 inhibitors stratified by ER, PR, HER2 expression levels and Ki-67 in hormone receptor-positive, HER2 negative metastatic breast cancer: Real-world outcomes	Maya Gogtay
P3-05-27: Real-world evidence on the use of the 21-gene assay in prognostically intermediate luminal breast cancer (BC): experience from a French multicenter cohort (N=1,126)	Natacha Joyon
P3-05-28: A clinical risk prediction model for subsequent invasive breast cancer after ductal carcinoma in situ	Charlotta Mulder
P3-05-29: Seven in Absentia Homolog (SIAH) expression and clinicopathological correlates in early-stage triple-negative breast cancer (TNBC)	Roberto Leon-Ferre
P3-05-30: Clinically Advanced Neuroendocrine Carcinoma of the Breast (CANECB): A Genomic Landscape Study	Melissa Taylor
P3-06-01: Occupational exposure to ionizing radiation in female physicians and risk of breast cancer: a systematic review and meta-analysis	Yedda Reis

P3-06-02: Prenatal diethylstilbestrol (DES) exposure and risk of benign breast disease	Paloma Mitra
P3-06-03: Multi-drug adherence and breast cancer recurrence: A nationwide study of US veteran women with breast cancer and depression	Maya Aboumrاد
P3-06-04: The effect of socioeconomic status on late-stage breast cancer by race and estrogen receptor status: Insights from the Carolina Breast Cancer Study	Joel Begay
P3-06-05: Real-world impact of remote symptom monitoring program on hospitalizations and emergency room visits in women with breast cancer	Gabrielle Rocque
P3-06-06: Associations between social drivers of health and breast cancer stage at diagnosis among US Black women	Mollie Barnard
P3-06-07: Plant-based Diets and Risk of Breast Cancer: A Pooled Analysis of 21 Cohorts	Emily Riseberg
P3-06-08: Chemotherapy decision making and physical and psychological symptoms in young breast cancer survivors	Krystal Wright
P3-06-09: Effect of a 6-Month Tailored Exercise Program According to Cancer Trajectories in Patients with Breast Cancer: Preliminary Results of a Randomized Controlled Trial	Su Jin Yeon
P3-06-10: Triple Negative Breast Cancer: The standpoint of Mexican population	Ma. Fernanda Noriega-Iriondo
P3-06-11: Efficacy of a Structured Educational Program in Enhancing Breast Cancer Knowledge Among Caregivers in Egypt: A Quasi-Experimental Pilot Study	Emad Shash
P3-06-12: Breast Cancer and Mortality Rates: An Analysis Using the NIS 2021 Database	Kalaivani Babu
P3-06-13: Prevalence and Effect of Comorbidities on Survival of Breast Cancer Patients by age	Bombi Park
P3-06-14: Evaluating “Spinning Science” A Patient-Led Health Literacy Educational Program for People Living with Metastatic Breast Cancer	Mya Roberson
P3-06-15: Trajectories of Daily Step Counts in Breast Cancer Survivors in the Breast Cancer Weight Loss (BWEL) Trial	Chao Cao
P3-06-16: Heterogeneity of Tertiary Lymphoid Structures Predicts the Response to Neoadjuvant Therapy and Immune Microenvironment Characteristics in Triple-Negative Breast Cancer	Chuangui Song, Chuangui Song
P3-06-17: IAPP mediated anti-breast cancer function of CD8+T cells via targeting cuproptosis	Zhijian Huang

P3-06-18: Novel regulators of PDGF-BB secretion in breast cancer	Jesse Reardon
P3-06-19: Spatial multicolor assay for assessing immune cell phenotype and function in the tumor microenvironment	Anushka Dikshit
P3-06-20: Lean adipocyte-secreted oxylipin, 9S-HODE, triggers ferroptosis and protects against obesity-accelerated breast cancer	Meghan Curtin
P3-06-21: Needle Biopsy Accelerates Pro-Metastatic Changes and Systemic Dissemination in ER+ Breast Cancer: Implications for Mortality by Surgery Delay	Takemi Tanaka
P3-06-23: Determining organotropic drivers of metastasis in a new genetically engineered mouse model	Eran Andrechek
P3-06-24: Characterization of a Living Biobank of Patient-Derived Invasive Lobular Carcinoma Organoids that Retain Tumor Heterogeneity in 3D Culture and Tumorigenicity In Vivo.	Minakshi Gandhi
P3-06-25: Humanized patient-derived xenograft models of triple-negative breast cancer for analyzing the safety and effectiveness of mRNA lipid nanoparticle cancer vaccines	Maria Chervo
P3-06-26: p53 Haploinsufficiency Epistatically Masks A3B Tumor Phenotype in vivo	Joshua Proehl
P3-06-27: Immunotherapy and PI3K/mTOR inhibition combination to mediate metastasis and immunotherapy resistance in triple-negative breast cancer	John Friend
P3-06-28: Neo-adjuvant administration of MDNA11, a long-acting IL-2 Superkine, prevents metastasis, protects against tumor rechallenges and provides long-term survival in an orthotopic model of breast cancer	Minh To
P3-06-29: Circulating tumor cell expansion from frozen PBMCs enables drug screening against metastatic tumor cells	Shian-Jiun Shih
P3-06-30: Novel Humanized LIV-1 Antibody Based ADCs Conjugated with Topoisomerase I Inhibitor Payloads Displayed Significantly Higher Anti-tumor Activities than MMAE based ADCs in TNBC Tumor Models	Xueming Qian
P3-07-01: Comparative effectiveness and safety of initial operation in inoperable locally advanced breast cancer—a real-world retrospective cohort study in China	Yan Lin
P3-07-02: Sentinel node biopsy alone versus sentinel node biopsy plus axillary dissection in cT2 cN0/1 breast cancer patients after neoadjuvant chemotherapy: 15 year results of a prospective interventional trial	Gabriele Martelli

P3-07-03: Real-world comparison of safety and effectiveness of dose dense (2-weekly) versus weekly paclitaxel given with trastuzumab as neoadjuvant treatment in HER2-positive early stage breast cancer.	Yael Berner-Wygoda
P3-07-04: Postoperative upper Limb Edema & Dysfunction Generated by axillary nodes Excision w/ or w/out axillary vein branches reservation in breast cancer patients (PLEDGE-Surgery): a prospective, multiple-center, double-blinded, randomized controlled study	Qianrui Xu
P3-07-05: An Application of the Air Inflation Adjustment Technique in Reverse Sequence Endoscopic Nipple Sparing Mastectomy with immediate breast reconstruction : A prospective cohort study	Kawun Chung
P3-07-06: Axillary Lymph Node Dissection or Not Among Women with Breast Cancer and Sentinel Lymph Node (SLN) Metastasis in Upfront Surgery: A Meta-Analysis of Randomized Trials	André Mattar
P3-07-07: Title: 10-Year Local Recurrence Rates Following Selective Omission of Re-excision for Patients with Ductal Carcinoma in Situ and Margins	Cecily Stockley
P3-07-08: Breast-Conserving Surgery in US Young Women With Early-Stage, HR-Positive/HER2-Negative Breast Cancer: National Trends and Oncologic Outcomes after Neoadjuvant Systemic Therapy	Jincong Freeman
P3-07-09: Cost Differences of Hospital Admission vs. Home Recovery following Mastectomy	Leah Kim
P3-07-10: Omitting axillary dissection in Triple-negative and HER2-overexpressed cancers After neoadjuvant Chemotherapy: OTHER-NAC Study	Neslihan Cabioglu
P3-07-11: Avoidance of axillary lymph node dissection in patients with 1-2 pre-operative positive lymph nodes undergoing upfront surgery: 'Primary targeted axillary dissection' early outcomes	Radhika A Merh
P3-07-12: Breast-conserving surgery versus mastectomy in patients with locally advanced breast cancer.	Alexander Petrovsky, Viktoria Amosova
P3-07-13: Preoperative Predictors of Nodal pCR for Potential De-escalation of Axillary Surgery in Inflammatory Breast Cancer	Jennifer Chen
P3-07-14: Omitting axillary dissection in Triple-negative and HER2-overexpressed breast cancers with positive sentinel Lymph nodes during upfront surgery: OTHELLO Study	Neslihan Cabioglu

P3-07-15: VARIATION IN PRACTICE AND PROVISION OF CONTRALATERAL SYMMETRISING MASTECTOMY AFTER UNILATERAL MASTECTOMY FOR BREAST CANCER: A UK NATIONAL PRACTICE SURVEY	Katherine Fairhurst
P3-07-16: Validation of a Novel Prognostic Staging System for De Novo Metastatic Breast Cancer: A Real-World Experience	Ibrahim Khamees
P3-07-17: Adjuvant Therapy in Patients with Positive Lymph Nodes Post-Neoadjuvant Chemotherapy With and Without Axillary Lymph Node Dissection	Anthony Baez
P3-07-18: Sacituzumab Govitecan in Metastatic Breast Cancer: Impact of Age and BRCA Mutational Status in a Real-World Cohort	Alexandre de Nonneville
P3-07-19: Survival Outcomes in Breast Cancer with Brain Metastasis Based on Prior Lines of Systemic Therapy for Metastatic Disease	Harkarandeep Singh
P3-07-20: New Wine in Old Bottles - The Therapeutic Promise of the PARP Inhibitor Rucaparib as an N-WASP Inhibitor for Breast Cancer Metastasis	Rhiannon Yannan Yu
P3-07-21: Transcriptomic analysis of the tumor immune microenvironment (TIME) in patients with breast cancer with liver metastasis (BCLM)	Jiayi Tan
P3-07-22: A miRNA expression profiling of breast cancer to develop a metastases predictor model and identify new molecular players of metastatic outgrowth.	Paola Parrella
P3-07-23: Incidence, Risk Factors, and Survival Outcomes of Brain Metastases in Breast Cancer Patients: Insights from a Tertiary Care Center	Nafisa Abdelhafiez
P3-07-24: Real-World Treatment Patterns and Clinical Outcomes of Sacituzumab Govitecan in HER2 negative metastatic breast cancer patients in China	Huanhuan Zhou
P3-07-25: Current Treatment Strategies for PIK3CA-Mutated Metastatic Breast Cancer and Provider Perceptions of the INAVO120 Trial	Brooke Leon
P3-07-26: Inpatient outcomes and predictors of mortality in Leptomeningeal carcinomatosis in patients with breast cancer	RAJ SHAH
P3-07-27: Selective De-Escalation of Surgery: Trends in Surgical Management of de Novo Stage IV Breast Cancer Over the Past Decade	Jennifer Chen
P3-07-28: Anxiety, Depression and Coping Mechanisms Among Young Women Diagnosed with De Novo Metastatic Breast Cancer	Leticia Varella

P3-07-29: ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells in Metastatic Breast Cancer	Karthik Giridhar
P3-07-30: Mesenchymal Stem Cells Regulate E-cadherin Level, Proliferation, and Immuno-Resistance on Breast Cancer Cells	Bei Dai
P3-08-01: Cardiovascular and Non-cardiovascular Risks among Female Breast Cancer Survivors in Japan: A Matched Cohort Study	Chitose Kawamura
P3-08-02: Real-world Evidence: Pegylated Liposomal Doxorubicin 40mg/m ² versus 50 mg/m ² in Patients with Metastatic Breast Cancer.	Daniel Agustin Vasquez
P3-08-03: Trends in Presentation of HER2+ Breast Cancer: A Retrospective study of De Novo Versus Recurrent Metastatic Breast Cancer (MBC) in the Real-World French National ESME Cohort (2008-2022)	Thomas Grinda
P3-08-04: Prevalence of HER2-ultralow subtype and outcome among patients with HR-positive (HR+) HER2-negative (HER2-) metastatic breast cancer receiving first line chemotherapy. A real-world single center study.	Laurent Mathiot
P3-08-05: Cyclin inhibitors for breast cancer: A comparative real world data analysis	Julio Cesar Betiol
P3-08-06: Clinical Activity of Sacituzumab Govitecan in Metastatic Triple Negative and Hormone Receptor Positive, HER-2 Negative Breast Cancer	Nicole Yun
P3-08-07: A real-world analysis of clinical characteristics and outcomes of early-stage, triple-negative breast cancer patients receiving anthracycline-sparing neoadjuvant chemoimmunotherapy: the Mayo Clinic experience	Tanmayi Pai
P3-08-08: Clinical and financial impact of implementation of Oncotype Dx in women with HR positive HER2 negative early breast cancer treated in a Chilean Cancer Center.	Roxana Allende
P3-08-09: Clinicopathological feature based risk of recurrence in pT2N0 HR-positive and HER2-negative early breast cancer as included in NATALEE-trial: a retrospective, real-world, monocentric study	Rik Van Severen
P3-08-10: Real-world treatment patterns and clinical outcomes for patients with metastatic triple-negative breast cancer (mTNBC) in the United States: an electronic health records observational study	Tiffany Traina
P3-08-11: Clinico-Pathological Features of Breast Cancer Patients Who Recured After Achieving pCR with Neoadjuvant Chemotherapy before Surgery (KBCSG-18)	Jee Hung Kim

P3-08-12: Poor Response of Metaplastic Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy: An Unmet Oncological Need	Sara Cartwright
P3-08-13: Measuring the impact of Komen's Financial Assistance program on the treatment experience of those living with MBC	Shelby Lautner
P3-08-14: Analysis of the Occurrence Time of Bone Metastasis and Disease Treatment Patterns in 737 Patients with Breast Cancer Bone Metastasis: A Retrospective Study from China	Xiaojia Wang
P3-08-15: Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Healthcare: A Real-World Study	André Mattar
P3-08-16: TADPOLE: A multicentre, pragmatic, phase III randomised controlled trial comparing Targeted Axillary Dissection vs axillary node clearance in patients with PPositive axillary Lymph nodes in Early breast cancer	Shelley Potter
P3-08-17: TBCRC 058: A Randomized Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, & Treatment of Physician's Choice in Patients with Androgen Receptor-Positive Metastatic Triple-Negative or Estrogen Receptor-Low Breast Cancer (NCT06099769)	Rita Nanda
P3-08-18: The AmeliaTM-1 study: A phase 1b/2 study assessing the safety and efficacy of evexomostat (SDX-7320) plus a PI3K/Akt inhibitor and fulvestrant in patients with advanced HR+/Her2-breast cancer	Peter Cornelius
P3-08-19: Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3K \hat{K} -H1047R, in mutant selected solid tumors including breast cancer.	Samuel Agresta
P3-08-20: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In Situ	Rachel Rabinovitch
P3-08-21: Trastuzumab-deruxtecan in HER2-low metastatic breast cancer patients with newly diagnosed or progressing brain metastases: The TUXEDO-4 phase II trial	Maximilian Marhold
P3-08-22: Tucatinib, Trastuzumab and Capecitabine with brain and/or spinal radiotherapy (XRT) in patients with HER2+ metastatic breast cancer and leptomenigeal disease: A multi-centre phase II, single arm feasibility study ("CLIMB LMD"; NCT06016387)	Katarzyna J. Jerzak

P3-08-23: Using a SMART Approach to Culturally-Adapt and Remotely Deliver a Weight Loss Intervention for Latina Breast Cancer Survivors: The ¡Vida! Study Methods	Blake Langley
P3-08-24: Valemetostat and Trastuzumab Deruxtecan in Patients With HER2-Low, Previously Treated, Unresectable or Metastatic Breast Cancer	Sara M. Tolaney
P3-08-25: randomized phase III study comparing the digital telemonitoring platform "CUREETY TECHCARE" to usual standard of care in patients with triple negative metastatic breast cancer initiating a first-line systemic treatment: ALTERNATIVE	Jerome MARTIN-BABAU
P3-08-26: Imipramine: A Promising Therapeutic Regimen for Breast Cancer Patients	Manjeet Rao
P3-08-27: Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer	Andrei Bakin
P3-08-28: VRTX531: A Novel Best-in-Class USP1 Inhibitor for the Treatment of Triple-Negative Breast Cancer	RISHI RAHANGDALE
P3-08-29: Early Clinical Experience with TTX-MC138, a First-in-Class Therapeutic Candidate for Metastatic Breast Cancer	Zdravka Medarova
P3-08-30: Development of humanized anti-FABP4 monoclonal antibodies for potential treatment of breast cancer	Bing Li
P3-09-01: Time to postmastectomy radiotherapy in the setting of immediate implant-based breast reconstruction: does it impact on adjuvant treatment delay compared with mastectomy alone?	Lilian Paz
P3-09-03: Cost effectiveness analysis of approaches to axillary management in the setting of contralateral prophylactic mastectomy	Christopher Vetter, Jeffrey Johnson
P3-09-04: Does additional margin excision during LumiSystem pegulicianine fluorescence-guided lumpectomy surgery affect patient breast satisfaction?	Barbara Smith
P3-09-05: ROBOTIC VS. CONVENTIONAL NIPPLE-SPARING MASTECTOMY IN BREAST CANCER: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS	Ana Threzeza's
P3-09-06: Predictors of axillary lymph node pathological complete response in clinical T4 breast cancer after neoadjuvant chemotherapy: results from a reference center in Brazil	Lilian Paz
P3-09-07: Prospective cohort study of oncological outcomes following partial breast reconstruction with chest wall perforator flaps to facilitate breast conservation in breast cancer.	Pankaj Roy

P3-09-08: Cryoablation in the Treatment of Early Breast Cancer - FIRST (Freezing bReaST cancer in Brazil): A Before-and-After Study	Vanessa Monteiro Sanvido
P3-09-09: Axillary staging techniques and oncologic outcomes for breast cancer patients with high clinical nodal burden undergoing neoadjuvant systemic therapy: A cancer registry study	André Pfob
P3-09-11: Effect of Removed Lymph Nodes Number on Survival in Node-negative Early Breast Cancer: A Multicenter Retrospective Study (CSOBO YOUNG-03)	Ke-Da YU
P3-09-12: Impact of Extracapsular Extension on Recurrence in Sentinel Lymph Node Positive Breast Cancer Patients: A Retrospective Cohort Study	Hyelim Kang
P3-09-13: Applicability of SOUND trial in the practice of breast-conserving surgery at tertiary-care hospital in Thailand	Lakkana Adireklarpwong
P3-09-14: SHIELD study: Reoperation Rate in Breast-Conserving Surgery using Confocal Histolog® Scanner for Intraoperative Margin Assessment	Michael P Lux
P3-09-15: Is it possible to recruit and randomise participants to an implant-based breast reconstruction trial in the UK? Results from the Best-BRA Study	Shelley Potter
P3-09-16: SerpinE2 mediated cell competition during breast cancer metastasis to the liver	Sakshi Mohta
P3-09-17: Trastuzumab deruxtecan (T-DXd) in combination with capecitabine or capivasertib in patients with HER2-low metastatic breast cancer: a Phase 1b, multicenter, open-label study (DESTINY-Breast08)	Komal Jhaveri
P3-09-18: Comparative analysis of protein and gene expression of biomarkers and therapeutic targets in patients with metastatic hormone-receptor positive breast cancer of no-special type versus invasive lobular breast cancer	Gitte Zels
P3-09-19: Tumor genomics in young patients with metastatic breast cancer	Kristen Brantley
P3-09-20: Re-evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 0 or 1+ in Metastatic Breast Cancer (mBC) Samples to Characterize the Proportion of HER2-ultralow (IHC 0 With Membrane Staining)	Savitri Krishnamurthy
P3-09-21: Phase IB/II Trial of Alpelisib with iNOS Inhibitor and Nab-paclitaxel in Patients with HER2 negative Metastatic or Locally Advanced Metaplastic Breast Cancer	Polly Niravath

P3-09-22: Phenomenal: Efficacy and safety of liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases	Manuel Ruiz Borrego
P3-09-23: Investigating differences in the composition of circulating tumor cells (CTCs) clusters in invasive lobular and ductal carcinoma to decipher lobular breast cancer metastasis	Eleonora Nicolò
P3-09-24: PLEURAL T CELLS FROM PATIENTS WITH METASTATIC INVASIVE LOBULAR CARCINOMA PRODUCE EFFECTOR CYTOKINES AND MOUNT ANTI-TUMOR IMMUNITY	Vera Donnenberg
P3-09-25: Fam-trastuzumab Deruxtecan-nxki Versus Chemotherapy as Post-Chemotherapy Treatment in Patients with HER2-Low Metastatic Breast Cancer: An Analysis Of Real-World Data from the IntegraConnect PrecisionQ De-Identified Database	Stephan Rosenfeld
P3-09-26: Efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic lobular breast cancer with or without HER2 mutations: the MSKCC experience	Sherry Shen
P3-09-27: Identification of glucocorticoid receptor dependence in metastasis of invasive lobular carcinoma using an in vivo xenograft MIND model	Baylee Porter
P3-09-28: Long-term follow-up on survival outcomes in patients developing ipsilateral breast tumor recurrences.	Changhoon Lee
P3-09-29: A Novel BBB-permeable Agent for Breast Cancer Brain Metastases	Mariana K. Najjar
P3-09-30: Sequential ADC Treatments in Metastatic Breast Cancer	Hannah Chang
P3-10-01: Interval Improvement in Overall Survival of Patients with De Novo Metastatic Breast Cancer. Real World Data from a Resource-Restricted Country	0 0
P3-10-02: Real-world study of Abemaciclib in Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: a Multi-Institutional Prospective Study	Elena Fountzilias
P3-10-03: Real-world first-line immunotherapy use and overall survival rates for triple-negative breast cancer: analyses from a 2018-2020 US population-based cohort	Dionisia Quiroga
P3-10-04: Outcomes following less-than-standard therapy in operable breast cancer patients	Alan Celik
P3-10-05: Real-World Efficacy of Fam-Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer	Sarah Blocker

P3-10-06: Missed opportunities: understanding the factors contributing to non-receipt of neoadjuvant chemotherapy in breast cancer patients	Daniela Vazquez-Juarez
P3-10-07: 10y overall survival (OS) in patients (pts) with breast cancer (BC) at a comprehensive cancer center in Colombia	ANA FIDALGO
P3-10-08: Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States	Elyse Swallow
P3-10-09: Prognostic implications of HER2 changes after neoadjuvant chemotherapy: A real world data of matched breast cancers with the inclusion of HER2-Low category	Marcelo Antonini
P3-10-10: Sequencing PIK3CA and AKT Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Retrospective Analysis	Rachel Abelman
P3-10-11: Breast Cancer Patient Navigation Program Saves Lives: Brazilian Experience in a Real-World Setting in the Public Health System	Sandra Gioia
P3-10-12: Retrospective analysis of adverse events and outcomes of patients receiving neoadjuvant pembrolizumab for triple negative breast cancer in Australia.	Evon Jude
P3-10-13: A Comprehensive Analysis of Dysregulation in the PTEN/PI3K/AKT Pathway in Breast Cancer Among the Chinese Population	Ziang Li
P3-10-14: Tolerability of First-Line (1L) Treatment (tx) With Ribociclib (RIB) for Metastatic Breast Cancer (MBC) Using 2 Large US Data Sources	Sarah Sammons
P3-10-15: Prognostic impact of progesterone receptor status in patients with breast cancer and with isolated locoregional recurrence: A retrospective cohort study based on the Japanese Breast Cancer Registry	Takeshi Murata
P3-10-16: Phase I/II of Personalized Neoantigen Peptide-Based Vaccine (PNeoVCA) in Combination with Pembrolizumab in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy	Saranya Chumsri
P3-10-17: Phase I/II study of the novel radioligand therapy [177Lu]Lu-NeoB plus capecitabine in patients w/ ER+/HER2- advanced breast cancer (ABC) w/GRPR expression after progression on prior endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i) for ABC	Mario Campone

P3-10-18: Phase II Single Arm Trial of Low Dose Capecitabine in Patients with Advanced Breast Cancer (NCT06105684)	Vinod Kumar
P3-10-19: Phase II Trial of Pembrolizumab in Combination with Olaparib in Advanced Breast Cancer with BRCA-mutation or Homologous Recombination Defect (HRD)	Jin Sun Bitar
P3-10-20: Phase II study of talazoparib, a PARP inhibitor, in HER2-metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in cell-free DNA or tumor tissue genotyping	Neelima Vidula
P3-10-21: Phase Ib dose-finding study of [177Lu]Lu-NeoB + ribociclib + fulvestrant in patients w/ ER+/HER2- advanced breast cancer (ABC) w/ GRPR expression w/ early relapse from (neo)adjuvant endocrine therapy (ET) or progression on ET + CDK4/6i for ABC	Debasish Tripathy
P3-10-22: Preoperative radiotherapy versus postoperative radiotherapy after neoadjuvant chemotherapy in high-risk breast cancer: a prospective, randomized, international multicentre Phase III trial—NeoRad	Christiane Matuschek
P3-10-23: RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer: APRIL Trial	Lei Lei
P3-10-24: Refusal of sentinel lymph node biopsy in patients with luminal A subtype of early breast cancer	Alexander Emelyanov
P3-10-25: Repeat Breast Conserving Surgery Followed by Daily Partial Irradiation for Patients w/ Ipsilateral Breast Tumor Recurrence or new Ipsilateral Primary Breast Cancer, Previously Treated w/ Breast Conserving Surgery & Whole Breast Radiation Therapy	Courtney Pisano
P3-10-26: SERIES: SEquencing Sacituzumab Govitecan (SG) After Trastuzumab Deruxtecan (T-DXd) In ER+/HER2 LOW MetaStatic Breast Cancer	Reshma Mahtani
P3-10-27: SMALL: Open Surgery versus Minimally invasive vacuum-Assisted excision for small screen-detected breast cancer – a UK phase III randomized multi-centre trial	Stuart A McIntosh
P3-10-28: Sentinel Lymph Node Biopsy vs Observation After Neoadjuvant Treatment (SLOAN)	Alexander Emelyanov, Nikolay Amirov
P3-10-29: Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387) - On the way to identify women at risk of developing seroma after mastectomy	Nina Ditsch
P3-10-30: Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer	Jose Bazan

P3-11-03: De-escalation of chemotherapy in patients with HER2-positive, hormone receptor negative, node-negative early breast cancer: primary results of the phase II DECRESCENDO trial	Elisa Agostinnetto
P3-11-04: Treatment Patterns and Outcomes associated with the use of Neoadjuvant Chemotherapy (NACT) among Patients with Early-stage HER2-Positive Breast Cancer (BC)	Inimfon Jackson
P3-11-05: Three-year efficacy and safety of neoadjuvant chemotherapy with pertuzumab, atezolizumab, docetaxel, and trastuzumab in patients with stage II/III ERBB2-positive breast cancer (NeoPATH): a nonrandomized, multi-institutional, phase 2 trial	Junghoon Shin
P3-11-06: Predicting the pathological response to neoadjuvant therapy using untargeted metabolomics in HER2-positive breast cancer	Marija Križić
P3-11-07: HER2 determination by ERBB2-mRNA expression analysis	Martina Vetter
P3-11-08: Treatment patterns and impact of adjuvant chemotherapy and targeted therapy on outcomes in HER2+ microinvasive breast cancer	Abha Kulkarni
P3-11-09: Incidence and Treatment Patterns of High-Risk HER2+ Early-Stage Breast Cancer Patients in the United States Community Oncology Setting	Sandhya Mehta
P3-11-10: Benefit/risk relationship of TCH versus AC-TH in BCIRG 006: analysis using generalized pairwise comparisons	Marc Buyse
P3-11-11: Ductal Carcinoma in Situ: Molecular and Cellular Basis of Malignant Transition	Fariba Behbod
P3-11-12: (Neo)adjuvant Therapy Patterns and Outcomes in Patients with HR-Positive/HER2-Positive Early or Locally Advanced Breast Cancer: a Real-World Study Using National Cancer Information Database, China	Zhenzhen Liu
P3-11-13: Efficacy and Safety of Chemo-Free Regimens in HER2-Positive Early Breast Cancer: A Comprehensive Systematic Review and Meta-Analysis	Zaheer Qureshi
P3-11-14: Differential response to neoadjuvant antiHER2 therapy between HER2 2+ISH+ and HER2 3+ in HER2-positive breast cancer: Is HER2 2+ISH+ a distinct subtype?	Lingjun Ma
P3-11-15: De-escalating neoadjuvant chemotherapy in early HER2+ breast cancer: a retrospective case series	Patricia Avancena

P3-11-16: Personalized Neoadjuvant Therapy Guided by Drug Screening of Patient-Derived Tumor-Like Cell Clusters in HER2-Positive Breast Cancer: A Prospective Phase II Study and Exploratory Analysis	Yaqian Xu
P3-11-17: A Randomized Phase II Trial of Neo-adjuvant Chemotherapy with Metformin or Placebo for HER-2 Positive Operable Breast Cancer (The HERMET Trial)	Maire Okoniewski
P3-11-18: Prognostic significance of lobular versus ductal histology in HER2-positive breast cancer	Alison Laws
P3-11-19: Efficacy of different neoadjuvant systemic treatment regimens in Chinese patients with HER2-positive advanced breast cancer: a real-world retrospective multi-center cohort study	Xiaoming Zha
P3-11-20: 2018 and 2024 surveys of clinical investigator (CI) use of postoperative systemic therapy after prior neoadjuvant treatment of HER2-positive breast cancer (HER2+BC)	Neil Love
P3-11-21: Sociodemographic Factors Associated with Use of Adjuvant Therapy in Stage I Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer	Fauzia Riaz
P3-11-22: Extended adjuvant neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine – interim analysis of the multinational, prospective, non-interventional study ELEANOR (n=300)	Diana Lüftner
P3-11-23: A multicentre UK Study of the impact of progesterone receptor status on pathological complete response rate and outcomes in 1037 patients with HER-2 positive, early breast cancer treated with neoadjuvant chemotherapy, trastuzumab and pertuzumab	James Pearson
P3-11-24: Neoadjuvant Nab-paclitaxel combined with Trastuzumab and Pyrotinib for HER2-enriched subtype of HER2-positive early or locally advanced breast cancer: A multicenter, single-arm, phase 2 trial	Wenbin Zhou
P3-11-25: Use of the MammaTyper® Platform to Reclassify Breast Tumors by the Expression of HER2	SERAFIN MORALES
P3-11-26: A Phase II study of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer	Xiaohua Zeng, Xinrui Liang
P3-11-27: Pathologic Complete Response and Residual Cancer Burden as Powerful Prognostic Markers in HER2-Positive Early Breast Cancer: A Comprehensive Real-World Study	Emad Shash

P3-11-28: HER2+ Breast Cancer: Loss of HER2 and Disease Prognosis After Neoadjuvant Treatment - A Pertuzumab effect?	Francisco Paralta Branco
P3-11-29: Early change in lymphocyte count on neoadjuvant therapy (NAT) and treatment response in patients with HER2+ breast cancer (BC)	Colin Bergstrom
P3-11-30: Low Ki67 is associated with a lower pathological complete response rate after neoadjuvant therapy in HER2-positive breast cancer patients.	BRUNNA SILVA
P3-12-01: Eribulin in HER2-negative breast cancer. Results of real world data (RWD) in the era of precision oncology.	Diego Martín Sánchez
P3-12-02: Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant in Hormone Receptor (HR)-Positive, HER2-Negative Premenopausal Women with Metastatic Breast Cancer. Real World Data from a Resource-Restricted Country	0 0
P3-12-03: Optimizing Treatment Sequence for Inoperable LABC: Long-Term Outcomes of Surgery First vs. Neoadjuvant Chemotherapy in a Real-World Setting	Yu Song
P3-12-04: Aromatase Inhibitors versus tamoxifen for Elderly Breast Cancer Patients: A Retrospective Study on the Survival Outcomes	Jinyoung Byeon
P3-12-05: Real-world use of sacituzumab govitecan (SG) in the management of metastatic triple-negative breast cancer (mTNBC) through a Canadian Patient Support Program (PSP)	Pierre-Luc Tanguay
P3-12-06: Locoregional and contralateral breast tumor events within 5 years after diagnosis of primary breast cancer in the Netherlands: a population-based study including 121,426 breast cancer patients	Sabine Siesling
P3-12-07: SARELIFE study: Safety and efficacy of Sacituzumab Govitecan (SG) in pretreated metastatic triple negative breast cancer (mTNBC): a multicentric, real-life study	Nicla La Verde
P3-12-08: Results of the cohort w/ central nervous system (CNS) metastasis in the real-world evidence observational study SACISUR, patients treated w/ Sacituzumab-Govitecan (SG) in triple neg metastatic breast cancer (mTNBC) clinical practice in the south	Alejandro Falcón-González
P3-12-09: Evaluation of the Early Risk of Recurrence in HR+/HER2-Early Breast Cancer Patients – A Retrospective Study Based on the Chinese National Cancer Database	Qiao Li

P3-12-10: Utilizing Registry Data to Explore Treatment Patterns in HR+ HER2-Negative Metastatic Breast Cancer: Insights from Denmark and Norway	Anja Reithmeier
P3-12-11: Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival on hormone receptor-positive metastatic breast cancer patients receiving targeted therapies	Jeffrey Franks
P3-12-12: Real-World Efficacy and Outcomes of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer: A Retrospective Analysis from Russia	Anastasia Danilova
P3-12-13: Malignant phyllodes tumor of the breast	Tatiana Titova
P3-12-14: Real world data with standard (SD) and reduced dose (RD) sacituzumab-govitecan (SG) in metastatic triple negative (TNBC) and ER+/HER2- metastatic breast cancer (mBC)	Naji Mallat
P3-12-15: Oncologists' Prescribing Habits for Adjuvant Therapy in Luminal Breast Cancer: Insights from a Low Middle Income Setting	Emad Shash
P3-12-16: MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4 / iBRA-NET, NCT 05559411)	Maggie Banys-Paluchowski
P3-12-17: NCT05074290 Phase I/II study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients	Coy Heldermon
P3-12-18: NEOMET: A phase II randomized trial to evaluate the impact of "targeted" nutritional support and exercise on modulation of metabolic and immune-related markers in early breast cancer (eBC) patients candidate to neoadjuvant therapy (NAT)	Ida Tagliatela
P3-12-19: NRG-BR008: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO)	Melissa Mitchell
P3-12-20: NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and Oncotype Recurrence Score (RS) ≤ 25 (OFSET)	Shannon Puhalla
P3-12-21: NeoTAILOR: A phase II biomarker-directed approach to guide neoadjuvant therapy for patients with clinical stage II/III ER+, HER2- negative breast cancer	Nusayba Bagegni

P3-12-22: Neoadjuvant Therapy with Pyrotinib, Subcutaneous Trastuzumab, and Capecitabine for HER2-Positive Early Breast Cancer: A Prospective, Single-Arm, Multicenter Trial	LiNa Zhang
P3-12-23: PATIENT ENGAGEMENT IN RESEARCH: CINDERELLA TRIAL AND LESSONS LEARNT FROM SCREENING FAILURES	André Pfob
P3-12-24: PREMO CNS: PREsentation, Management and Outcomes of patients with CNS disease secondary to breast cancer in England	Carlo Palmieri, Talvinder Bhogal
P3-12-25: PRSONAL - Population-based Randomized Study Of a Novel breast cancer risk ALgorithm and stratified screening	Stig Bojesen
P3-12-26: Partial breast re-irradiation using ultra hypofractionation: A Phase 2 multi- institutional study	Danielle Rodin
P3-12-27: Phase 1 Analysis from the PYNACLE Phase 1/2 Study of Rezatapopt in the Subgroup of Patients with Advanced Breast Cancer Harboring a TP53 Y220C Mutation	Ecaterina Dumbrava
P3-12-28: Phase 1b study of EZH1/2 inhibitor valemestostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer	Toshiaki Iwase
P3-12-29: Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) cells in Advanced GD2-expressing Breast Cancers (DiG NKs)	Margaret Gatti-Mays
P3-12-30: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic HER2 negative breast cancer	Sangeetha Reddy